Abstract One of the most common diseases of the pancreas is diabetes mellitus. The current treatment of exogenous insulin supply is not fully capable of achieving tight control of glucose regulation, leading to long-term complications. Hence, recent success in islet transplantation-based therapies for diabetes mellitus and the extreme shortage of pancreatic islets have motivated recent efforts to develop renewable sources of islet-replacement tissue. Of clinical interest, I review the recent progress on stem cell-based strategies for diabetes in view of regenerative medicine.
and colleagues showed that 10% of the 65 patients remained insulin free for 5 years after islet transplantation. 2 Although long-term insulin-free status has not been achieved in most patients, islet transplantation is encouraging.
However, the chronic shortage of organ donors has prevented a widespread use of islet transplantation, as in other organ or tissue transplantation. Hence, advances in cellreplacement strategies for diabetes and the shortage of transplantable pancreatic islets have focused on renewable sources of glucose-responsive, insulin-producing cells (IPCs). Of clinical interest, I review here the recent progress on stem cell-based strategies for diabetes.
Embryonic stem cells (ESCs)
The use of human embryonic stem cells (ESCs) attracts tremendous public attention for reasons of their pluripotency and the ease of generating large numbers in culture. However, there are still many limitations in using ESCs as therapeutic tools, notably the lack of reliable methods for generating specifi c lineages and the diffi culty of purifying specifi cally differentiated progeny and avoiding immunological rejection of the transplanted cells. 3 Furthermore, once they are transplanted, it is almost impossible to control development of the transplanted ESCs into specifi c cell lineages. Despite these problems, the potential application of ESCs in regenerative medicine provides great impetus to studies of the molecular genetic nature of the stem cell state. Figure 1 summarizes the strategy for regenerative medicine using ESCs. If IPCs or islet-like cell differentiation from patient-derived ESCs can be achieved, we can promise to provide immune-tolerant and customized cell therapy for diabetic patients.
Selection of nestin-positive cells to generate IPCs from ESCs
At an early stage of ESC research to generate IPCs, we and others focused on the selection of cells positive for nestin, [4] [5] [6] an intermediate fi lament protein that serves as a neural stem/progenitor marker. 7 Islets are the principal source of insulin in humans, but in some invertebrate species, such as Drosophila, brain neurons are the main source of circulating insulin. 8, 9 The similarities between islet cells and neurons are further underscored by the demonstration of insulin gene transcription in the vertebrate brain, 10 although it remains unclear whether these vertebrate neurons produce or secrete insulin protein. 11 Recent reports have shown that nestin is a marker for neural progenitors and pancreatic exocrine progenitor cells but not endocrine progenitor cells, 12, 13 suggesting that nestin-positive cells from ESCs likely generate neuronal cell types. Consequently, ESCderived IPCs may produce insulin at a much lower level compared with pancreatic β cells. This hypothesis is in agreement with our previous report. 14 We have shown that brain-derived human neural progenitor cells, when exposed to a series of signals that regulate in vivo pancreatic islet development, form clusters of glucose-responsive IPCs. 14 We calculate that C-peptide content in IPCs derived from human neural progenitor cells is approximately 0.3% of the level in isolated pancreatic β cells. While much attention has been focused on the promise of ESCs, recent work suggests that neural stem cells, similar to ESCs, may have an unusually broad differentiation potential. For example, Gage and colleagues demonstrated the conversion of mouse neural stem cells to the endothelial lineage, indicating that plasticity is a bona fi de property of cultured neural stem cells. These results were unexpected because endothelial cells and neuronal cells normally derive, respectively, from mesoderm and ectoderm, distinct embryonic germ layers. 15 Further investigation is necessary to determine whether ESC-derived nestin-positive cells may differentiate into fully functional IPCs.
Differentiation of ESCs following embryonic pancreas development
Embryonic pancreas development requires the stepwise activation of several signaling pathway (Fig. 2) . 16, 17 To generate fully differentiated IPCs, attempts for mimicking embryonic endoderm development and pancreas specifi cation are emerging. Recent reports have shown the effi cient differentiation of pancreatic lineage from ESCs. 18, 19 The fi rst step from ESCs toward the pancreatic lineage is defi nitive endoderm (DE) formation. Previous studies implicated transforming growth factor (TGF)-β and Wnt signals as critical signals for DE formation in vivo. 20, 21 Activin A, a member of the TGF-β family, was thus used at high concentration to induce DE, 22 in combination with Wnt3a. 18, 19, 23, 24 More recently, we showed effi cient differentiation of ESCs into mesoderm and endoderm using the tetracycline transactivator system to drive expression of nodal, the most notable endogenous molecule to induce the formation of mesoderm and endoderm. 25 Nodal-expressing cells differentiated toward a mesendodermal progenitor population, a transient tissue that gave rise to both the mesodermal and endodermal germ layer more effi ciently than exogenous activin treatment. 25 Notably, sustained nodal expression in mouse ESCs maintained Oct4 levels and prevented the differentiation of DE cells. Upregulation + pancreatic epithelium. 5. Endocrine cells proliferate and mature toward the islet of Langerhans, aggregates of insulin-producing β cells. TGF-β, transforming growth factor-β; RA, retinoic acid; SHH, sonic hedgehog; FGF, fi broblast growth factor; VEGF, vascular endothelial growth factor and subsequent downregulation of nodal signaling resulted in the maturation of DE, which showed expression including TTF-1, SftpC, albumin (foregut marker), pancreatic duodenal homeobox 1 (Pdx1), glucagon (midgut marker), IFABP, and villin (hindgut marker). Unfortunately, we were unable to detect insulin gene expression in our system.
The next crucial step is the induction of pancreatic epithelium. A previous report has shown that suppression of sonic hedgehog (Shh) activity is required for the specifi cation of pancreatic buds. 26 Addition of cyclopamine, an inhibitor of the Hedgehog signaling pathway by blockade of Smoothend, 27, 28 promotes the formation of pancreatic epithelium marked by Pdx1 expression, the master gene for pancreas organogenesis. 18, 19 Retinoic acid induces development of primitive endodermal cells from a subset of embryonal carcinoma cell lines and is an endogenous signal that directs development of posterior organs such as the pancreas from embryonic endoderm. 14, 29, 30 Addition of retinoic acid promotes the commitment of the Pdx1-positive pancreas progenitors toward the endocrine lineage. 18, 19 However, ESC-derived hormone-producing endocrine cells have not yet achieved full maturation.
Differentiation of IPCs by a genetic approach
Previous reports have shown pancreatic differentiation could be achieved through exogenous Pdx1, Ngn3, and Pax4 expression in ESCs, although functional IPCs were not generated. 6, 31, 32 The level, timing, and duration of forced expression of these transcription factors are important. 25 Prolonged overexpression of Pdx1 failed to induce the specifi cation of IPCs. 33 In addition, precocious expression of Ngn3 during pancreas development results in the predominant formation of α-cells at the expense of other endocrine cell types. 34, 35 Induced pluripotent stem (iPS) cells iPS cells have been derived from fi broblasts by ectopic expression of the transcription factors Oct4, Sox2, c-myc, and Klf4. 36 iPS cells are molecularly and functionally highly similar to ESCs, including their ability to contribute to all tissues as well as the germline in mice. We questioned and expected if iPS cells derived from somatic cells with a specifi c cell fate might be susceptible to differentiate toward original somatic cells. Reprogramming is not only restricted to mesodermal derivatives but is also possible with endodermal cell types, including stomach, liver, and pancreatic insulin-producing β cells. 37, 38 So far, there has been no evidence that iPS cells persist in the susceptibility to differentiate toward original somatic cells. In addition, it remains to be shown that iPS cells have the same capacity as human ESCs for differentiation toward β cells. A recent report described that human iPS derived from skin fi broblasts indeed can give rise to IPCs. 39 Taken together, although ESCs or iPS cells hold a promising potential as a source of IPC, IPC clusters from these stem cells still have a high degree of cellular heterogeneity, tumor-forming potential, and low insulin levels compared with pancreatic islets. More recently in Japan, speculations by researchers about the future clinical implication of iPS cells have been published. It will take more than 10 years until clinical cell-replacement therapy for diabetes and liver failure is achieved, suggesting that we still have a major hurdle to differentiate ESCs or iPS toward fully matured endodermal cells.
Tissue-specifi c pancreatic stem/progenitor cells
Recent studies in regenerative medicine have also focused on the isolation and characterization of repopulating tissuespecifi c stem/progenitor cells. However, only a few attempts have been made at the prospective isolation of pancreatic stem/progenitor cells because of the lack of specifi c markers and the failure to develop a cell culture strategy to determine their capacity for self-renewal and multilineage potential.
Adult pancreatic stem/progenitor cells
Putative adult pancreatic stem/progenitor cells that clonally expand while expressing a low level of insulin and other pancreatic markers have been found in the mouse pancreas. 40, 41 However, their capacity for self-renewal and the ability to differentiate into functional islets remain undetermined. The use of adult stem cells isolated from patients can provide an excellent solution to immunological problems raised in cell therapies. The main problem with this approach is that adult stem cells are rare and diffi cult to expand in culture. In contrast, Dor et al. reported that new β cells, after birth, could be generated by the replication of existing β cells, rather than by putative pancreatic stem cells. 42 Upon injury, insulin-producing β cells are also produced from endogenous endocrine progenitors. 43 Taken together, the existence of adult pancreatic stem/progenitor cells and their signals to expand still remain controversial.
Embryonic pancreatic stem/progenitor cells
On the other hand, there is no doubt that pancreatic stem/ progenitor cells exist in the developing pancreas. The pancreas develops from the posterior foregut, emerging as buds from the ventral and dorsal area of the gut tube. A key component and a central transcription factor of pancreatic development is Pdx1. Pdx1 was identifi ed based on its ability to bind the insulin and somatostatin genes. In the early pancreas, Pdx1 is expressed throughout the epithelium, but then is suppressed in cells as they commit to the endocrine or ductal cell lineage. As endocrine cells begin to differentiate to the insulin-producing β-cell lineage, Pdx1 reappears, and its expression in β cells is known to be necessary for de novo insulin synthesis. Although it is thought that Pdx1-expressing epithelial progenitor cells give rise to endocrine, exocrine, and ductal cells, 44 evidence that isolated clonogenic cells are pancreatic stem/progenitor cells with characteristics indicating the capability for self-renewal and pluripotency still remains to be achieved.
We have recently established the prospective isolation of putative pancreatic epithelial progenitor cells by sorting for cell-surface markers. 45 First, the expression of stem cell markers in pancreatic buds was examined at mouse embryonic day (E) 11.5 and E13.5, when the majority of the epithelium consists of undifferentiated progenitor cells, and we observed CD133 (mouse prominin1) expression on the apical membrane of the Pdx1-expressing pancreatic epithelial cells (Fig. 3) . CD133 expression has been previously Fig. 3 . CD133 is expressed on the Pdx1 + pancreatic epithelium, whereas platelet-derived growth factor receptor-β (PDGFR-β) is expressed on the surrounding mesenchyme at E11.5 and E13.5 mouse embryonic pancreas shown in putative stem/progenitor cells in brain, 46 kidney, 47 prostate, 48 and ES-derived progenitors. 49 More recently, CD133 expression has also been reported in neonatal and adult pancreatic ductal progenitor cells 50 and fetal islet progenitor cells. 51 Previous efforts to expand the number of β cells and other pancreatic epithelial cells were limited by mesenchyme-derived fi broblast overgrowth in vitro culture. To rule out any other tissue-derived progenitor cells, including hematopoietic and neural progenitor cells, and to further establish an in vitro culture system, it is necessary to distinguish the epithelial cells from the surrounding mesenchymal cells. We observed that platelet-derived growth factor receptor-β (PDGFR-β, also known as CD140b) was expressed on the mesenchymal cells within the embryonic pancreas (Fig.  3) . We obtained subpopulations by fl uorescence-activated cell sorting (FACS) using CD133 and PDGFR-β, and pancreatic stem/progenitor cells were enriched in the CD133 high PDGFR-β − fraction by reverse transcription-polymerase chain reaction (RT-PCR) and DNA microarray (Fig. 4 , not shown). Although we were unable to differentiate these cells toward all pancreatic cell lineages in culture, they differentiated all pancreatic cells, including ductal, endocrine, and exocrine cells, after engraftment with mesenchymal cells. 45 It is noted that the concept of stem cells has been extended from hematopoietic stem cells to many other tissues; until now, however, only rarely have stem cells been identifi ed as clonogenic precursors that include in their progeny those with both self-renewing and differentiated potential. Based strictly on this defi nition, stem cells reported in other tissues are not clonogenic. Of interest, an encouraging study has recently reported that single Lgr5 stem cells build crypt-villus structures in vitro. 52 
Stem/progenitor cells from other sources
The stem/progenitor cells of other sources also might be expanded and transdifferentiated into IPCs under specifi c conditions. These studies have provided many candidates, including human neural progenitor cells, 14 hepatic oval cells, 53 umbilical cord blood-derived stem cells, 54 placentaderived multipotent stem cells, 55 and bone marrow-derived mesenchymal stem cells. 56, 57 Additional studies in vivo, including rescue of diabetic phenotype in mice, appear to be necessary to indicate the clinical benefi t of using these stem/progenitor cells.
Conclusion and future
Cell-replacement strategy for diabetic patients using stem/ progenitor cells has become a promising therapy because of their capacity to self-renew and potential to differentiate into the pancreatic cell lineage. Advances in understanding the mechanism underlying pancreas development and regeneration, including specifi c intrinsic and extracellular signals that govern the switch between the self-renewal and differentiation of pancreatic stem/progenitor cells, are necessary for further clinical benefi t.
